Skip to contentV
Valion Bio, Inc.
V
VBIOValion Bio, Inc. Q3 2024 · 10-Q
Revenue$126.00K$126.00K−55.3% vs Q3 2023 Net Income-$1.43M-$1.43MN/M vs Q3 2023 EPS Diluted-$0.23-$0.23N/M vs Q3 2023 Gross Profit$44,000−59.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,407,000N/M Margins · derivedGross margin34.9%−3.4 pt vs Q3 2023
Operating margin-1135.7%−511.6 pt vs Q3 2023
Net margin-1135.7%−511.6 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end